Prot# SHP-141-001: A Randomized, Double-blind, Placebo-Controlled, Dose-Escalating, Phase 1B Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP-141, A Histone Deacetylase Inhibitor, Administered Topically up to 28 Days to Patients wi